Influenza A virus vaccine H5N1 - iBio

Drug Profile

Influenza A virus vaccine H5N1 - iBio

Alternative Names: HAI-05 Influenza Vaccine; Pandemic avian influenza vaccine - iBio; Plant virus derived influenza vaccine - iBio

Latest Information Update: 02 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator INB:Biotechnologies
  • Developer iBio Inc
  • Class Influenza A virus H5N1 vaccines; Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Influenza A virus H5N1 subtype

Most Recent Events

  • 30 Nov 2015 Phase I development is ongoing in USA
  • 30 Nov 2015 iBio has patent protection for iBioModulator™ thermostable immunomodulator protein technology in China
  • 05 Mar 2013 Phase-I development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top